ASICS Experiment Reveals Just One Week of Physical Inactivity Has a Similar Impact as a Week of Broken Sleep on Our State of Mind
30.3.2022 02:01:00 EEST | Business Wire | Press release
Today, the impact of physical inactivity on our mental state has been revealed for the first time in the Mind Racei – an ASICS experiment in which regular exercisers paused their normal fitness routines for one week. The impact on their state of mind was found to be similar to a week of broken sleepii, with participants reporting a 23% increase in racing thoughts.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220329005848/en/
Participants including Olympian, Iwan Thomas take part in the ASICS Mind Race – a first-of-its-kind study which revealed that not exercising for a week has the same negative impact on our state of mind as seven nights of broken sleep. Extending this research with the ASICS Uplifting Minds Study also revealed that just 15 minutes and 9 seconds of exercise is enough to boost our mental wellbeing. This global study sampled thousands of participants from across the globe during an 8 month period. (Photo: Business Wire)
Reassuringly, the results of ASICS’ Uplifting Minds Studyiii, involving thousands of participants from across the globe, proves it can take just 15:09 minutes of physical activity to lift our mental state – even after periods of inactivity.i
The Mind Race: just one week of inactivity significantly lowers our state of mind
Professor Brendon Stubbs, a leading researcher in movement and the mind, monitored the State of Mindiv scores of healthy participantsv who agreed to pause their regular exercise routines for just one week. The results are significant with both their cognitive and emotional wellbeing being impacted. When active people stopped moving, their confidence dropped by 20%; positivity fell by 16%, energy levels slumped by 23% and their ability to cope with stress reduced by 22%.
In fact, after just one week of no exercise, participants’ overall State of Mind score dropped by an average of 18% - decreasing from a high 68 out of 100 when physically active to a mediocre 55 out of 100 when they stopped exercising. The effects of this inactivity are captured in the Mind Race experiment film asics.com/mindrace , following a group of study participants.
Just 15 minutes of activity can uplift our state of mind
But there is good news. Participants were monitored when they returned to their regular exercise regime and all experienced immediate improvements in their state of mind – showing how quickly the negative effects of inactivity can be reversed. Professor Brendon Stubbs also analysed data from thousands of people who participated in ASICS' ongoing Uplifting Minds Study since June 2021. The Study uses cutting edge technology to mimic EEG and capture the impact of exercise on people’s state of mind. Based on data from across sports and across regions, just 15.09 minutes of exercise can significantly impact our mental state.
Commenting on the results, Professor Brendon Stubbs said: “We know that exercise is good for our mental health but the impact of rest and restarting exercise is less clear. Now, thanks to new technology and the contribution of thousands of people, we’ve been able to pinpoint just how much exercise is needed to trigger a positive mental impact. This ASICS study helps to quantify the amount of exercise to improve mental health and make it more tangible. Taking time to rest is very important. This study shows that people’s wellbeing bounces back very quickly after a period of rest when people resume regular exercise again.”
Gary Raucher, EVP, ASICS EMEA said: “Our founding philosophy is literally in our name, Anima Sana In Corpore Sano or a Sound Mind in a Sound Body. And we believe our focus on the benefits of sport and movement, not just on the body, but also on the mind, has never been more relevant. We know the last two years have been tough on the mental state of many. And while not the answer for everyone, we know exercise can make a difference. We hope to inspire more people to move with ASICS, even for just 15.09 minutes to feel the benefits on body and mind.”
To be part of ASICS’ ongoing Uplifting Minds Study and see the impact of exercise on your own State of Mind, visit https://minduplifter.asics.com/
Notes to Editors
Download imagery
Watch video link
For further information, images or to organize an interview with Professor Brendon Stubbs, please contact Asics@Golin.com
ASICS’ Uplifting Minds Study enables people all over the world to measure the impact of movement on their mind. Using cutting edge facial scanning technology and self-reported data, ASICS has measured the impact of exercise on thousands of minds from 79 countries over a 10-month period.
ASICS’ Mind Race, a three-week extension of the study, measured what happened to the minds of 58 regular exercisers from 21 countries when they stopped exercising for just one week. Using self-reported data, qualitative questionnaires and cutting-edge technology, the study pinpointed the effects of both physical activity and inactivity on participants mental wellbeing.
___________
i ASICS’ Mind Race Study 2022
ii Comparison drawn from Soomi Lee, Naturally Occurring Consecutive Sleep Loss and Day-to-Day Trajectories of Affective and Physical Well-Being, Annals of Behavioral Medicine, 2021, DOI: 10.1093/abm/kaab055
iii ASICS’ Uplifting Minds Study 2021-2022
iv ASICS proprietary State of Mind score is a rating out of 100 made up of 10 emotional and cognitive metrics, including: composure, resilience, positivity, contentment, relaxation, confidence, alertness, calmness, focus and energy.
v Volunteers who passed the screening criteria and consented to participate. Screening criteria included: adults (age 18+), already physically active (doing more than 150 minutes of moderate to vigorous exercise per week) and willing to stop exercising for one week with the belief it would not have a detrimental impact on their mental health.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220329005848/en/
Contact information
Rory Cramsie
asics@golin.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
